晚期肝細胞癌全身性治療的新趨勢

New Trands in the Treatment of Advanced Hepatocellular Carcinoma

10.6880/TJON.200912/SP_9.01

邵幼雲(Yu-Yun Shao)；林宗哲(Zhong-Zhe Lin)；洪敏瑛(Ming-Ying Hong)

肝癌 ； 標靶治療 ； 臨床試驗 ； 化學治療 ； hepatocellular carcinoma ； targeted chemotherapy ； clinical trails ； cytotoxic chemotherapy

腫瘤護理雜誌

9卷S期（2009 / 12 / 01）

1 - 12

繁體中文

晚期肝細胞癌的治療一直是個艱難的挑戰。細胞毒性化學治療藥物的副作用很大，但治療效果卻相當令人失望。最近sorafenib被證實可延長這些病人的存活，為這群病人的治療帶來一絲曙光。然而，sorafenib的腫瘤反應率並不高，病人的存活時間也仍不理想。因此在近年內，許多新藥開始了晚期肝癌的臨床試驗。雖然這些新藥的發展可能帶來令人振奮治療進步，但這些新藥的確實效用仍需大型三期臨床試驗的證實。

The treatment of advanced hepatocellular carcinoma has been challenging for a long time. Cytotoxic chemotherapeutic agents were generally too toxic for these patients, and their tumor responses were disappointedly low. Sorafenib, the first drug proven to provide survival benefit for patients with advanced hepatocellular carcinoma, has shed a light into the treatment of this disease. However, the low response rate and limited survival prolongation of sorafenib left much to be improved. In recent years, the development of clinical trials for advanced hepatocellular carcinoma is booming. Despite some promising preliminary results, the therapeutic benefit of these novel targeted agents should be confirmed in phase III trials.